Cardiovascular diagnosis and therapy最新文献

筛选
英文 中文
L-shaped association between gamma-glutamyl transferase-to-albumin ratio and dabigatran-related bleeding in non-valvular atrial fibrillation patients: a multicenter cohort study. 非瓣膜性心房颤动患者γ-谷氨酰转移酶-白蛋白比值与达比加群相关出血之间的L型关联:一项多中心队列研究。
IF 2.1 3区 医学
Cardiovascular diagnosis and therapy Pub Date : 2024-10-31 Epub Date: 2024-10-22 DOI: 10.21037/cdt-24-258
Chao Yu, Tao Wang, Lingjuan Zhu, Wei Zhou, Huihui Bao, Xiaoshu Cheng
{"title":"L-shaped association between gamma-glutamyl transferase-to-albumin ratio and dabigatran-related bleeding in non-valvular atrial fibrillation patients: a multicenter cohort study.","authors":"Chao Yu, Tao Wang, Lingjuan Zhu, Wei Zhou, Huihui Bao, Xiaoshu Cheng","doi":"10.21037/cdt-24-258","DOIUrl":"https://doi.org/10.21037/cdt-24-258","url":null,"abstract":"<p><strong>Background: </strong>The correlation between the gamma-glutamyl transferase-to-albumin ratio (GAR) and the risk of bleeding in patients with non-valvular atrial fibrillation (NVAF) undergoing treatment with the dabigatran anticoagulant is poorly understood. This study aims to explore whether GAR is associated with bleeding events among patients with NVAF receiving dabigatran anticoagulant therapy.</p><p><strong>Methods: </strong>We conducted a multicenter, observational cohort study in 12 Chinese hospitals from six provinces, including Beijing, Shanghai and Guangzhou, to evaluate the effectiveness and safety of dabigatran (110 mg) treatment in NVAF patients who were consecutively enrolled during February 2015 and December 2017. All patients had completed a 3-month follow-up period. The baseline variable of interest was the GAR, and the outcome variable was the occurrence of bleeding events. Both univariate and multivariate Cox proportional hazard models were used to evaluate the relationship between GAR and bleeding outcome.</p><p><strong>Results: </strong>This prospective cohort study included a total of 834 patients (mean age 65.6±11.1 years; 56.8% male). Overall, 82 subjects experienced bleeding. The patients were categorized based on the tertiles of the GAR. Participants in tertile 2 (0.59-1.03) [hazard ratio (HR): 0.28; 95% confidence interval (CI): 0.14-0.55; P<0.001] and tertile 3 (≥1.04) (HR: 0.47; 95% CI: 0.25-0.89; P=0.02) exhibited a lower rate of bleeding compared to the reference group (T1: ≤0.58). Multivariable models with restricted cubic splines demonstrated a nonlinear relationship between GAR and bleeding outcome, with a GAR inflection point of 0.68. The HR (95% CI) was 0.05 (0.01-0.31) (P=0.002) for GAR values <0.68 and 0.96 (0.70-1.31) (P=0.78) for GAR values ≥0.68. Moreover, the correlation between decreased GAR and an increase in bleeding events remained consistent across various subgroups.</p><p><strong>Conclusions: </strong>GAR is a prevalent, independent predictor of dabigatran-related bleeding in NVAF patients. Moreover, a significant L-shaped association between GAR and bleeding events has been observed.</p>","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 5","pages":"848-858"},"PeriodicalIF":2.1,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Secondary mitral regurgitation surgical management: a narrative review. 继发性二尖瓣反流手术治疗:综述。
IF 2.1 3区 医学
Cardiovascular diagnosis and therapy Pub Date : 2024-10-31 Epub Date: 2024-09-24 DOI: 10.21037/cdt-24-6
Sarah R Eapen, Mina H Zaky, Megan P Kostibas, Michael P Robich
{"title":"Secondary mitral regurgitation surgical management: a narrative review.","authors":"Sarah R Eapen, Mina H Zaky, Megan P Kostibas, Michael P Robich","doi":"10.21037/cdt-24-6","DOIUrl":"https://doi.org/10.21037/cdt-24-6","url":null,"abstract":"<p><strong>Background and objective: </strong>The most common valvular heart disease in the US is moderate to severe mitral regurgitation (MR). Function MR or secondary MR comprises many of these cases. Moderate and severe secondary MR are independently associated with increased all-cause mortality and rehospitalization for heart failure. Both ischemic and nonischemic cardiomyopathy can cause secondary MR via similar pathophysiology that leads to inadequate valve leaflets coaptation. The management of secondary MR is complex. The optimal treatment strategy for secondary MR remains controversial, reflected in the vast array of treatment options and the complexity of therapeutic decision-making. Several surgical mitral valve repair techniques have been described in the literature. Many of these aims to facilitate adequate valve leaflet coaptation. In this review, the pathophysiology of MR is described with a focus on evaluating and managing secondary MR.</p><p><strong>Methods: </strong>A literature review was performed using PubMed and Google Scholar. Clinical trials, meta-analyses, randomized controlled trials, reviews, and systematic reviews were considered from January 1, 1995 through December 31, 2022. Articles published in languages other than English with limited text availability were excluded.</p><p><strong>Key content and findings: </strong>Optimal therapeutic approach in severe secondary MR is complex and several patient factor should be considered. We provide a framework for the surgical management of secondary MR based on echocardiographic parameters, the presence of ischemia, and myocardial viability.</p><p><strong>Conclusions: </strong>Further study is needed to guide the selection of patients most likely to benefit from mitral valve repair or replacement in the setting of secondary MR.</p>","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 5","pages":"958-973"},"PeriodicalIF":2.1,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary hypertension in adults with congenital heart defects (ACHDs) in light of the 2022 ESC PAH guidelines-part II: supportive therapy, special situations (pregnancy, contraception, non-cardiac surgery), targeted pharmacotherapy, organ transplantation, special management (shunt lesion, left ventricular disease, univentricular hearts), interventions, intensive care, ACHD follow-up, future perspective. 根据 2022 年 ESC PAH 指南,探讨先天性心脏缺陷(ACHD)成人的肺动脉高压问题--第二部分:支持性治疗、特殊情况(怀孕、避孕、非心脏手术)、针对性药物治疗、器官移植、特殊管理(分流病变、左心室疾病、单心室心脏)、干预措施、重症监护、ACHD 随访、未来展望。
IF 2.1 3区 医学
Cardiovascular diagnosis and therapy Pub Date : 2024-10-31 Epub Date: 2024-10-22 DOI: 10.21037/cdt-24-167
Harald Kaemmerer, Gerhard Paul Diller, Ingo Dähnert, Stephan Achenbach, Christina A Eichstaedt, Andreas Eicken, Annika Freiberger, Sebastian Freilinger, Ralf Geiger, Matthias Gorenflo, Ekkehard Grünig, Alfred Hager, Michael Huntgeburth, Ann-Sophie Kaemmerer-Suleiman, Rainer Kozlik-Feldmann, Astrid E Lammers, Nicole Nagdyman, Sebastian Michel, Kai Helge Schmidt, Mathieu Suleiman, Anselm Uebing, Fabian von Scheidt, Ulrike Herberg, Christian Apitz
{"title":"Pulmonary hypertension in adults with congenital heart defects (ACHDs) in light of the 2022 ESC PAH guidelines-part II: supportive therapy, special situations (pregnancy, contraception, non-cardiac surgery), targeted pharmacotherapy, organ transplantation, special management (shunt lesion, left ventricular disease, univentricular hearts), interventions, intensive care, ACHD follow-up, future perspective.","authors":"Harald Kaemmerer, Gerhard Paul Diller, Ingo Dähnert, Stephan Achenbach, Christina A Eichstaedt, Andreas Eicken, Annika Freiberger, Sebastian Freilinger, Ralf Geiger, Matthias Gorenflo, Ekkehard Grünig, Alfred Hager, Michael Huntgeburth, Ann-Sophie Kaemmerer-Suleiman, Rainer Kozlik-Feldmann, Astrid E Lammers, Nicole Nagdyman, Sebastian Michel, Kai Helge Schmidt, Mathieu Suleiman, Anselm Uebing, Fabian von Scheidt, Ulrike Herberg, Christian Apitz","doi":"10.21037/cdt-24-167","DOIUrl":"https://doi.org/10.21037/cdt-24-167","url":null,"abstract":"<p><p>The number of adults with congenital heart defects (ACHDs) is steadily increasing and is about 360,000 in Germany. Congenital heart defect (CHD) is often associated with pulmonary hypertension (PH), which sometimes develops early in untreated CHD. Despite timely treatment of CHD, PH not infrequently persists, redevelops in older age, and is associated with significant morbidity and mortality. The revised European Society of Cardiology (ESC)/European Respiratory Society (ERS) 2022 guidelines for the diagnosis and treatment of PH represent a significant contribution to the optimized care of those affected. However, the topic of \"adults with congenital heart defects\" is treated only relatively superficially in this context. After the first part commenting on a broad range of topics like definition, epidemiology, classification, diagnostics, genetics, risk stratification and follow-up, and gender aspects, the second part focuses on supportive therapy, special situations (pregnancy, contraception, non-cardiac surgery), targeted pharmacotherapy, organ transplantation, special management [shunt lesion, left ventricular (LV) disease, univentricular hearts], interventions, intensive care, ACHD follow-up, and future perspective. In the present article, therefore, this topic is commented on from the perspective of congenital cardiology. By examining these aspects in detail, this article aims to fill the gaps in the existing guidelines and provide a more thorough understanding from the perspective of congenital cardiology.</p>","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 5","pages":"921-934"},"PeriodicalIF":2.1,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence machine learning based evaluation of elevated left ventricular end-diastolic pressure: a Cleveland Clinic cohort study. 基于人工智能机器学习的左心室舒张末压升高评估:克利夫兰诊所队列研究。
IF 2.1 3区 医学
Cardiovascular diagnosis and therapy Pub Date : 2024-10-31 Epub Date: 2024-10-22 DOI: 10.21037/cdt-24-128
Bo Xu, Michelle Z Fang, Yadi Zhou, Krishna Sanaka, Lars G Svensson, Richard A Grimm, Brian P Griffin, Zoran B Popovic, Feixiong Cheng
{"title":"Artificial intelligence machine learning based evaluation of elevated left ventricular end-diastolic pressure: a Cleveland Clinic cohort study.","authors":"Bo Xu, Michelle Z Fang, Yadi Zhou, Krishna Sanaka, Lars G Svensson, Richard A Grimm, Brian P Griffin, Zoran B Popovic, Feixiong Cheng","doi":"10.21037/cdt-24-128","DOIUrl":"https://doi.org/10.21037/cdt-24-128","url":null,"abstract":"<p><strong>Background: </strong>Left ventricular end-diastolic pressure (LVEDP) is a key indicator of cardiac health. The gold-standard method of measuring LVEDP is invasive intra-cardiac catheterization. Echocardiography is used for non-invasive estimation of left ventricular (LV) filling pressures; however, correlation with invasive LVEDP is variable. We sought to use machine learning (ML) algorithms to predict elevated LVEDP (>20 mmHg) using clinical, echocardiographic, and biomarker parameters.</p><p><strong>Methods: </strong>We identified a cohort of 460 consecutive patients from the Cleveland Clinic, without atrial fibrillation or significant mitral valve disease who underwent transthoracic echocardiography within 24 hours of elective heart catheterization between January 2008 and October 2010. We included patients' clinical (e.g., heart rate), echocardiographic (e.g., E/e'), and biomarker [e.g., N-terminal brain natriuretic peptide (NT-proBNP)] profiles. We fit logistic regression (LR), random forest (RF), gradient boosting (GB), support vector machine (SVM), and K-nearest neighbors (KNN) algorithms in a 20-iteration train-validate-test workflow and measured performance using average area under the receiver operating characteristic curve (AUROC). We also predicted elevated tau (>45 ms), the gold-standard parameter for LV diastolic dysfunction, and performed multi-class classification of the patients' cardiac conditions. For each outcome, LR weights were used to identify clinically relevant variables.</p><p><strong>Results: </strong>ML algorithms predicted elevated LVEDP (>20 mmHg) with good performance [AUROC =0.761, 95% confidence interval (CI): 0.725-0.796]. ML models showed excellent performance predicting elevated tau (>45 ms) (AUROC =0.832, 95% CI: 0.700-0.964) and classifying cardiac conditions (AUROC =0.757-0.975). We identified several clinical variables [e.g., diastolic blood pressure, body mass index (BMI), heart rate, left atrial volume, mitral valve deceleration time, and NT-proBNP] relevant for LVEDP prediction.</p><p><strong>Conclusions: </strong>Our study shows ML approaches can robustly predict elevated LVEDP and tau. ML may assist in the clinical interpretation of echocardiographic data.</p>","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 5","pages":"788-797"},"PeriodicalIF":2.1,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations between daytime napping, sleep duration, and depression and 15 cardiovascular diseases: a Mendelian randomization study. 日间小睡、睡眠时间、抑郁与 15 种心血管疾病之间的关系:孟德尔随机研究。
IF 2.1 3区 医学
Cardiovascular diagnosis and therapy Pub Date : 2024-10-31 Epub Date: 2024-10-15 DOI: 10.21037/cdt-24-313
Yilin Li, Parveen K Garg, Jing Wu
{"title":"Associations between daytime napping, sleep duration, and depression and 15 cardiovascular diseases: a Mendelian randomization study.","authors":"Yilin Li, Parveen K Garg, Jing Wu","doi":"10.21037/cdt-24-313","DOIUrl":"https://doi.org/10.21037/cdt-24-313","url":null,"abstract":"<p><strong>Background: </strong>Numerous studies have documented the effects of daytime napping, sleep duration, and depression on cardiovascular diseases (CVDs). However, the evidence has been gleaned from observational studies that might be riddled with confounding variables and the possibility of reverse causation bias. Therefore, the present study employed a Mendelian randomization (MR) methodology to meticulously explore the relationships between daytime napping, sleep duration, and depression, and the risk profiles of CVDs.</p><p><strong>Methods: </strong>Genome-wide significant genetic variants associated with daytime napping, sleep duration, and depression were used as the instrumental variables (IVs). Data on the genetic correlations between these IVs and 15 CVDs were derived from the United Kingdom (UK) Biobank, Finnish Genome Studies, and other large-scale collaborations. We conducted both univariate and multivariate MR analyses to assess the overall effects and mediated relationships after adjusting for potential confounders, including body mass index (BMI), smoking status, and type 2 diabetes. The effect sizes were estimated using inverse variance-weighted (IVW) regression.</p><p><strong>Results: </strong>The MR analysis revealed that an increased risk of heart failure (HF) [odds ratio (OR): 1.366; 95% confidence interval (CI): 1.013-1.842; P=0.04], coronary atherosclerosis (OR: 1.918; 95% CI: 1.257-2.927; P=0.003), myocardial infarction (MI) (OR: 1.505; 95% CI: 1.025-2.211; P=0.04), and coronary artery disease (CAD) (OR: 1.519; 95% CI: 1.130-2.043; P=0.006) was significantly associated with genetically predicted daytime napping. Prolonged sleep duration was found to be related to a reduced risk of HF (OR: 0.995; 95% CI: 0.993-0.998; P=2.69E-04), peripheral vascular disease (PVD) (OR: 0.984; 95% CI: 0.971-0.997; P=0.02), and CAD (OR: 0.997; 95% CI: 0.994-0.999; P=0.006). Additionally, a statistically significant positive relationship was observed between depressive disorders and the occurrence of atrial fibrillation (AF) (OR: 1.298, 95% CI: 1.065-1.583, P=0.01), indicating a heightened susceptibility. The multivariable MR analyses substantiated the reliability of the observed associations between daytime napping and the incidence of HF and CAD, following adjustments for genetically predicted BMI and smoking. The sensitivity analysis did not reveal any evidence of horizontal pleiotropy or heterogeneity, thus supporting the validity of the study's results.</p><p><strong>Conclusions: </strong>This MR investigation posits a potential causal nexus between daytime napping, sleep duration, and depression, and the genesis of CVDs, offering new perspectives on the prevention and management of CVDs.</p>","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 5","pages":"771-787"},"PeriodicalIF":2.1,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultra-fast-track cardiac anesthesia in minimally invasive cardiac surgery: a retrospective observational study. 微创心脏手术中的超快速心脏麻醉:一项回顾性观察研究。
IF 2.1 3区 医学
Cardiovascular diagnosis and therapy Pub Date : 2024-10-31 Epub Date: 2024-10-22 DOI: 10.21037/cdt-24-175
Tian Jiang, Li-Xin Wang, Hao-Kang Teng, Lin-Ting Xu, Xiao-Kan Lou, Yu Wang, Han-Wei Wei, Mei-Juan Yan
{"title":"Ultra-fast-track cardiac anesthesia in minimally invasive cardiac surgery: a retrospective observational study.","authors":"Tian Jiang, Li-Xin Wang, Hao-Kang Teng, Lin-Ting Xu, Xiao-Kan Lou, Yu Wang, Han-Wei Wei, Mei-Juan Yan","doi":"10.21037/cdt-24-175","DOIUrl":"https://doi.org/10.21037/cdt-24-175","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;There is no uniformity on the safety profile of ultra-fast-track cardiac anesthesia (UFTCA), and there is a lack of research on the postoperative lung function status of patients with UFTCA. This retrospective study was to examine the benefits of UFTCA on the postoperative recovery and pulmonary function of patients undergoing minimally invasive cardiac surgery (MICS).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This retrospective study was performed on patients who underwent MICS at Zhejiang Provincial People's Hospital between January 2022 and July 2023. Patients were retrospectively segregated into two groups: UFTCA group and conventional general anesthesia (CGA group). Primary endpoints encompassed differences in the duration of postoperative intensive care unit (ICU) stay and overall hospital stay. Secondary observations included in-hospital mortality rate, 3-month post-discharge survival rate, oxygenation indexes of preoperative (T0), immediately after extubation (T1), 6 hours after extubation (T2), and 12 hours after extubation (T3), use of high-flow nasal cannula oxygen therapy in the ICU, postoperative total chest drainage volume, and the rate of complications. Group comparisons were performed using grouped &lt;i&gt;t&lt;/i&gt;-tests and repeated measures analysis of variance (ANOVA).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The UFTCA group (n=327) demonstrated shorter ICU and hospital stays when compared with the CGA group (n=216) (P=0.001). At the immediately after extubation, the UFTCA group exhibited a decrease in oxygenation index [arterial oxygen partial pressure (PaO&lt;sub&gt;2&lt;/sub&gt;)/fraction of inspired oxygen (FiO&lt;sub&gt;2&lt;/sub&gt;)] accompanied by elevated alveolar-arterial oxygen tension difference [P(A-a)O&lt;sub&gt;2&lt;/sub&gt;] and respiratory index [P(A-a)O&lt;sub&gt;2&lt;/sub&gt;/PaO&lt;sub&gt;2&lt;/sub&gt;] values compared to the CGA group (P=0.001). However, by 12 hours after extubation, the UFTCA group manifested an improved PaO&lt;sub&gt;2&lt;/sub&gt;/FiO&lt;sub&gt;2&lt;/sub&gt; and diminished P(A-a)O&lt;sub&gt;2&lt;/sub&gt;/PaO&lt;sub&gt;2&lt;/sub&gt; values compared to the CGA group. The UFTCA group required high-flow oxygen therapy after extubation with greater frequency than the CGA group (P=0.001). However, neither the UFTCA nor CGA group had patients who needed reintubation (P&gt;0.05). No significant differences were observed in postoperative atelectasis and pulmonary edema rates between the groups (P&gt;0.05), the UFTCA group recorded a diminished total chest drainage volume postoperatively (P=0.001). Incidence of postoperative nausea and vomiting (PONV) was heightened in the UFTCA group (P=0.01), while the incidence of delirium was less frequent when compared with the CGA group (P=0.001).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;UFTCA demonstrates potential benefits in minimizing ICU and postoperative hospital stay in patients undergoing MICS. This approach also contributes to a reduction in postoperative chest drainage volume and a decreased likelihood of postoperative delirium. Despite the initial decline in l","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 5","pages":"740-752"},"PeriodicalIF":2.1,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary hypertension in adults with congenital heart defects (ACHDs)-in light of the 2022 ESC PAH guidelines-part I: definition, epidemiology, classification, diagnostics, genetics, risk stratification and follow-up, gender aspects. 先天性心脏缺陷(ACHDs)成人肺动脉高压--根据 2022 年 ESC PAH 指南--第一部分:定义、流行病学、分类、诊断学、遗传学、风险分层和随访、性别方面。
IF 2.1 3区 医学
Cardiovascular diagnosis and therapy Pub Date : 2024-10-31 Epub Date: 2024-10-22 DOI: 10.21037/cdt-24-148
Harald Kaemmerer, Gerhard Paul Diller, Ingo Dähnert, Stephan Achenbach, Christina A Eichstaedt, Andreas Eicken, Annika Freiberger, Sebastian Freilinger, Ralf Geiger, Matthias Gorenflo, Ekkehard Grünig, Alfred Hager, Michael Huntgeburth, Ann-Sophie Kaemmerer-Suleiman, Rainer Kozlik-Feldmann, Astrid E Lammers, Nicole Nagdyman, Sebastian Michel, Kai Helge Schmidt, Mathieu Suleiman, Anselm Uebing, Fabian von Scheidt, Ulrike Herberg, Christian Apitz
{"title":"Pulmonary hypertension in adults with congenital heart defects (ACHDs)-in light of the 2022 ESC PAH guidelines-part I: definition, epidemiology, classification, diagnostics, genetics, risk stratification and follow-up, gender aspects.","authors":"Harald Kaemmerer, Gerhard Paul Diller, Ingo Dähnert, Stephan Achenbach, Christina A Eichstaedt, Andreas Eicken, Annika Freiberger, Sebastian Freilinger, Ralf Geiger, Matthias Gorenflo, Ekkehard Grünig, Alfred Hager, Michael Huntgeburth, Ann-Sophie Kaemmerer-Suleiman, Rainer Kozlik-Feldmann, Astrid E Lammers, Nicole Nagdyman, Sebastian Michel, Kai Helge Schmidt, Mathieu Suleiman, Anselm Uebing, Fabian von Scheidt, Ulrike Herberg, Christian Apitz","doi":"10.21037/cdt-24-148","DOIUrl":"https://doi.org/10.21037/cdt-24-148","url":null,"abstract":"<p><p>The number of adults with congenital heart defects (ACHDs) is steadily increasing and is about 360,000 in Germany. Congenital heart defect (CHD) is often associated with pulmonary hypertension (PH), which sometimes develops early in untreated CHD. Despite timely treatment of CHD, PH not infrequently persists, redevelops in older age, and is associated with significant morbidity and lethality. The revised European Society of Cardiology (ESC)/European Respiratory Society (ERS) 2022 guidelines for the diagnosis and treatment of PH represent a significant contribution to the optimized care of those affected. However, the topic of \"adults with congenital heart defects\" is treated only relatively superficially in this context. In the present article, part I, therefore, this topic is commented on in detail from the perspective of congenital cardiology with a special focus on definition, epidemiology, classification, diagnostics, genetics, risk stratification and follow-up and gender aspects of PH in ACHDs. This paper consists of two parts. Part II will provide comments on the topics of supportive therapy, special situations like pregnancy, contraception, and non-cardiac surgery, targeted pharmacotherapy, organ transplantation, special management like shunt lesion, left ventricular disease, and univentricular hearts, interventions, intensive care, ACHDs follow-up and future perspective on PH in ACHDs. By examining these aspects in detail, this article aims to fill the gaps in the existing guidelines and provide a more thorough understanding from the perspective of congenital cardiology.</p>","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 5","pages":"935-948"},"PeriodicalIF":2.1,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of STK38L in atrial fibrillation-associated myocardial fibrosis: findings from RNA-seq analysis. STK38L 在心房颤动相关心肌纤维化中的作用:RNA-seq 分析的发现。
IF 2.1 3区 医学
Cardiovascular diagnosis and therapy Pub Date : 2024-10-31 Epub Date: 2024-10-22 DOI: 10.21037/cdt-24-164
Yu Zhang, Ru Zhang, Xiaochen Wang, Sihua Fang, Bangning Wang
{"title":"Role of STK38L in atrial fibrillation-associated myocardial fibrosis: findings from RNA-seq analysis.","authors":"Yu Zhang, Ru Zhang, Xiaochen Wang, Sihua Fang, Bangning Wang","doi":"10.21037/cdt-24-164","DOIUrl":"https://doi.org/10.21037/cdt-24-164","url":null,"abstract":"<p><strong>Background: </strong>Myocardial fibrosis is a key pathological feature of many cardiovascular diseases, leading to cardiac dysfunction. Transforming growth factor β1 (TGF-β1) induces the proliferation and activation of cardiac fibroblasts (CFs), key contributors to myocardial fibrosis. To explore the mechanism underlying myocardial fibrosis, we aimed to determine whether serine/threonine kinase 38 like (STK38L) contributes to the development of myocardial fibrosis by regulating the proliferation and activation of CFs triggered by TGF-β1.</p><p><strong>Methods: </strong>In this study, atrial tissue samples from atrial fibrillation (AF) patients with features of myocardial fibrosis (a category of atrial cardiomyopathy) and sinus rhythm (SR) patients without myocardial fibrosis were collected for RNA sequencing (RNA-seq). The specific molecule STK38L was identified. Primary mouse CFs were activated with TGF-β1 and subsequently transfected with STK38L-small interfering RNA (siRNA). The effect of STK38L-siRNA on fibroblast activation and proliferation was assessed using scratch and Cell Counting Kit-8 (CCK-8) assays. Furthermore, a mouse model of myocardial fibrosis induced by continuous subcutaneous injection of isoprenaline (ISO) was established to assess <i>STK38L</i> expression levels. Molecular experiments confirmed the expression of STK38L in fibrotic atrial tissues, ventricular tissues of ISO mouse, and primary CFs of neonatal mice.</p><p><strong>Results: </strong>We identified 1,870 genes exhibiting differential expression in the RNA-seq data between the AF and SR groups. Masson's trichrome staining revealed increased fibrosis in the heart tissues of the AF group. Elevated levels of STK38L were observed in the atrial tissues of the AF group and in the TGF-β1-stimulated primary mouse CFs. <i>In vitro</i>, STK38L knockdown suppressed mouse CFs activation and proliferation. Additionally, <i>in vivo</i> experiments showed that elevated mRNA levels of <i>STK38L</i>, periostin (<i>POSTN</i>), and collagen type I alpha 1 chain (<i>COL1A1</i>) in ISO-treated mouse hearts correlated with greater myocardial fibrosis, suggesting that STK38L plays an important role in the development of fibrosis.</p><p><strong>Conclusions: </strong>This study revealed a significant correlation between increased STK38L expression and AF characterized by atrial fibrosis as well as between STK38L expression and the TGF-β1-related induction of myocardial fibrosis. Additionally, STK38L knockdown was shown to suppress CFs activation and proliferation under TGF-β1 stimulation. These findings suggest an important role of STK38L in the development of fibrosis, and help screen for new strategies to treat this complex disease.</p>","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 5","pages":"798-809"},"PeriodicalIF":2.1,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Three-dimensional optical coherence tomography for guidance of percutaneous coronary intervention for coronary bifurcation disease: a review of current clinical applications. 三维光学相干断层扫描用于指导冠状动脉分叉疾病的经皮冠状动脉介入治疗:当前临床应用综述。
IF 2.1 3区 医学
Cardiovascular diagnosis and therapy Pub Date : 2024-10-31 Epub Date: 2024-10-18 DOI: 10.21037/cdt-24-163
Yang Li, Ryoji Nagoshi, Amane Kozuki, Yoichi Kijima, Yaling Han, Junya Shite
{"title":"Three-dimensional optical coherence tomography for guidance of percutaneous coronary intervention for coronary bifurcation disease: a review of current clinical applications.","authors":"Yang Li, Ryoji Nagoshi, Amane Kozuki, Yoichi Kijima, Yaling Han, Junya Shite","doi":"10.21037/cdt-24-163","DOIUrl":"https://doi.org/10.21037/cdt-24-163","url":null,"abstract":"<p><p>Percutaneous coronary intervention (PCI) for coronary bifurcation disease remains one of the most challenging situations in interventional cardiology in terms of procedural success rates and long-term cardiac events. Optical coherence tomography (OCT), with a higher signal-to-noise ratio and the ability to distinguish plaque components, can display the true condition of bifurcation lesions without overlapping or shortening and achieve detailed visualization of vascular structures, which is superior to those of other imaging modalities. Three-dimensional (3D) reconstruction of OCT images (3D-OCT) helps to gain a more informed understanding of the geometry and morphology of bifurcation lesions and provide additive information on plaque distribution. Following stent implantation, 3D-OCT can also guide the re-crossing of guide wires through stent struts jailing the side branch (SB) ostium and more clearly display the jailing strut configuration, as well as the ideal position of the guidewire recrossing point and stent struct link connection, to confirm the optimal guidewire position and understand interactions between stents and vessel walls, which may improve clinical results after PCI. The present review provides an up-to-date overview of the clinical use of 3D-OCT for accurate assessment of bifurcation anatomy, guiding the optimal guidewire rewiring into SB during bifurcation stenting, and evaluation of post-PCI results, offering novel information about atherosclerotic disease or stenting process.</p>","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 5","pages":"949-957"},"PeriodicalIF":2.1,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The image of a disabled person in art through the ages. 历代艺术中的残疾人形象。
IF 2.1 3区 医学
Cardiovascular diagnosis and therapy Pub Date : 2024-10-31 Epub Date: 2024-10-15 DOI: 10.21037/cdt-24-262
Liudmila Alexeevna Zotova, Victoria Alexandrovna Kotova
{"title":"The image of a disabled person in art through the ages.","authors":"Liudmila Alexeevna Zotova, Victoria Alexandrovna Kotova","doi":"10.21037/cdt-24-262","DOIUrl":"https://doi.org/10.21037/cdt-24-262","url":null,"abstract":"","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 5","pages":"982-986"},"PeriodicalIF":2.1,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信